AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35361684 — intervention group
Group type: EXPERIMENTAL
Intervention: AIEC identification within the surgical specimen
Number of subjects: 181
Study 35361684 — intervention group
Group type: EXPERIMENTAL
Intervention: History of positive test for AIEC (M0 or M6)
Number of subjects: 181
Study 35361691 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose vaccination
Number of subjects: 33
Study 35361691 — intervention group
Group type: EXPERIMENTAL
Intervention: Third SARS-CoV-2 vaccine
Number of subjects: 33
Study 35362047 — intervention group
Group type: EXPERIMENTAL
Intervention: CBLB-deficient CD8+ T cells
Number of subjects: 0
Study 35362065 — intervention group
Group type: EXPERIMENTAL
Intervention: Addressing social determinants of health/adverse childhood experiences in primary care
Number of subjects: 0
Study 35362065 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of primary care professionals and staff
Number of subjects: 0
Study 35362065 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral processes for additional evaluation or help
Number of subjects: 0
Study 35362192 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal buprenorphine
Number of subjects: 80
Study 35362522 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral therapy
Number of subjects: 161
Study 35362522 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent IDU with needle/syringe sharing
Number of subjects: 161
Study 35362522 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer HCV testing interval
Number of subjects: 161
Study 35362761 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo imaging methods to visualize and quantify the peripheral cholinergic nervous system
Number of subjects: 0
Study 35362761 — intervention group
Group type: EXPERIMENTAL
Intervention: Total volume-of-distribution rank order
Number of subjects: 0
Study 35362857 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid use in the second wave
Number of subjects: 9967
Study 35362857 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 9967
Study 35362857 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 9967
Study 35362857 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical care admission
Number of subjects: 9967
Study 35362857 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 9967
Study 35362862 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose estrogen/progestin (LEP)
Number of subjects: 397
Study 35362862 — intervention group
Group type: COMPARATOR
Intervention: Non-LEP treatment (NSAIDs or Chinese herbal medicines)
Number of subjects: 397
Study 35362878 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (4 capsules of 530 mg EPA, 150 mg DHA)
Number of subjects: 55
Study 35362878 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 55
Study 35362878 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 55
Study 35362878 — intervention group
Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 55
Study 35363144 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP QI training program
Number of subjects: 8
Study 35363144 — intervention group
Group type: COMPARATOR
Intervention: Standard implementation (adding a link to DecisionPrecision in the electronic health record)
Number of subjects: 8
Study 35363144 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing (AD)
Number of subjects: 8
Study 35363152 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine and exercise
Number of subjects: 30
Study 35363152 — intervention group
Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 30
Study 35363252 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal ingestion
Number of subjects: 20
Study 35363252 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion
Number of subjects: 20
Study 35363252 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal ingestion after bariatric surgery
Number of subjects: 20
Study 35363252 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP infusion after bariatric surgery
Number of subjects: 20
Study 35363252 — intervention group
Group type: COMPARATOR
Intervention: VAT perfusion response
Number of subjects: 20
Study 35363252 — intervention group
Group type: EXPERIMENTAL
Intervention: VAT perfusion response after bariatric surgery
Number of subjects: 20
Study 35363564 — intervention group
Group type: EXPERIMENTAL
Intervention: Gameplay of ≥1.5 hours/day in the non-LSC traits group (higher DP group)
Number of subjects: 1535
Study 35363623 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized-Targeted Computerized Cognitive Training
Number of subjects: 0
Study 35363631 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (BFT)
Number of subjects: 12
Study 35363631 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecobionics
Number of subjects: 12
Study 35363631 — intervention group
Group type: COMPARATOR
Intervention: Conventional technologies (ARM-BET)
Number of subjects: 12
Study 35363884 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics combined with ethanol lock solution
Number of subjects: 760
Study 35363884 — intervention group
Group type: COMPARATOR
Intervention: Tissue plasminogen activator (TPA) lock solution with concurrent systemic antibiotics
Number of subjects: 760
Study 35363884 — intervention group
Group type: COMPARATOR
Intervention: Catheter guidewire exchange
Number of subjects: 760
Study 35364421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles
Number of subjects: 104
Study 35364569 — intervention group
Group type: EXPERIMENTAL
Intervention: LCTOPC1 (2 × 10^6 cells) administered via intraparenchymal injection
Number of subjects: 5
Study 35364716 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid vulnerable plaques coexisting with lacunes
Number of subjects: 634
Study 35364716 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid vulnerable plaques coexisting with moderate-to-severe WMHs
Number of subjects: 634
Study 35364716 — intervention group
Group type: COMPARATOR
Intervention: Carotid vulnerable plaques
Number of subjects: 634
Study 35364716 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid vulnerable plaques coexisting with CSVDs
Number of subjects: 634
Study 35364716 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacunes
Number of subjects: 634
Study 35364716 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-severe WMHs
Number of subjects: 634
Study 35365547 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring for 3 days every fortnight for 12 weeks postpartum
Number of subjects: 300
Study 35365547 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour ambulatory blood pressure monitoring at 12 weeks postpartum
Number of subjects: 300
Study 35365547 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires completed by women and healthcare professionals regarding postpartum care and CVD risk knowledge
Number of subjects: 300
Study 35365547 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of hypertension and influencing factors (severity of HDP, maternal age, BMI, ethnicity)
Number of subjects: 300
Study 35365828 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL200 (200 mg daily)
Number of subjects: 3691
Study 35365828 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL100 (100 mg daily)
Number of subjects: 3691
Study 35365828 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 3691
Study 35365828 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL200
Number of subjects: 3691
Study 35365828 — intervention group
Group type: EXPERIMENTAL
Intervention: FIL100
Number of subjects: 3691
Study 35366263 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nutraceuticals for 6 months as part of a Mediterranean diet
Number of subjects: 0
Study 35366263 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 0
Study 35366312 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency treatment
Number of subjects: 5416
Study 35366312 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin deficiency treatment
Number of subjects: 5416
Study 35366312 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia due to iron deficiency
Number of subjects: 5416
Study 35366312 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia of inflammation
Number of subjects: 5416
Study 35366312 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of anemia on quality of life
Number of subjects: 5416
Study 35366378 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 142
Study 35366432 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sit-up test (bedside)
Number of subjects: 53
Study 35366570 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI/bev
Number of subjects: 1187
Study 35366570 — intervention group
Group type: COMPARATOR
Intervention: doublets/bev
Number of subjects: 1187
Study 35366613 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 'next-step' treatment strategies
Number of subjects: 0
Study 35366613 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific types of childhood adversities
Number of subjects: 0
Study 35366711 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated blood hemoglobin (HGB > 149.5 g/L)
Number of subjects: 800
Study 35366711 — intervention group
Group type: COMPARATOR
Intervention: Normal blood hemoglobin (HGB ≤ 149.5 g/L)
Number of subjects: 800
Study 35366805 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral treatment for HBV (20.3% of patients received this treatment)
Number of subjects: 1177
Study 35366805 — intervention group
Group type: COMPARATOR
Intervention: Patients without cirrhosis
Number of subjects: 1177
Study 35366805 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-withdrawal of nucleos(t)ide analog (NA)
Number of subjects: 1177
Study 35366805 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, cirrhosis at admission, and platelet level
Number of subjects: 1177
Study 35366820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum lipoarabinomannan (LAM) as a biomarker
Number of subjects: 776
Study 35366820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum lipoarabinomannan (LAM)
Number of subjects: 776
Study 35366820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum lipoarabinomannan (LAM) positivity
Number of subjects: 776
Study 35366825 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative accelerated partial breast irradiation (APBI) using CyberKnife, single fraction (exact dosage not specified)
Number of subjects: 0
Study 35366825 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative accelerated partial breast irradiation (APBI)
Number of subjects: 0
Study 35366848 — intervention group
Group type: EXPERIMENTAL
Intervention: KISS intervention (Knocking out Infections through Safer-sex and Screening)
Number of subjects: 79
Study 35366920 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (L-C)
Number of subjects: 157
Study 35366920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 35366963 — intervention group
Group type: EXPERIMENTAL
Intervention: Odronextamab (up to 320 mg once per week, with maintenance every 2 weeks after cycle 4)
Number of subjects: 145
Study 35366963 — intervention group
Group type: EXPERIMENTAL
Intervention: Odronextamab (doses of 5 mg or higher)
Number of subjects: 145
Study 35366963 — intervention group
Group type: EXPERIMENTAL
Intervention: Odronextamab (doses of 80 mg or higher)
Number of subjects: 145
Study 35366963 — intervention group
Group type: EXPERIMENTAL
Intervention: Odronextamab
Number of subjects: 145
Study 35367107 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider communication
Number of subjects: 1395
Study 35367107 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-appropriate care
Number of subjects: 1395
Study 35367107 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-sensitive communication
Number of subjects: 1395
Study 35367396 — intervention group
Group type: EXPERIMENTAL
Intervention: iNKT cell and PD-1+CD8+ T cell-based immunotherapy, infused every 3-5 weeks, considered 1 cycle.
Number of subjects: 3
Study 35367396 — intervention group
Group type: EXPERIMENTAL
Intervention: iNKT cell and PD-1+CD8+ T cell-based immunotherapy
Number of subjects: 3
Study 35367616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence guided photodynamic therapy (PDT) using a portable fibre-coupled LED system
Number of subjects: 30
Study 35367616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence guided photodynamic therapy (PDT)
Number of subjects: 30
Study 35367851 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic dose verification system with propagated contours
Number of subjects: 31
Study 35367908 — intervention group
Group type: EXPERIMENTAL
Intervention: Li-Fraumeni syndrome (LFS) experiences
Number of subjects: 117
Study 35367908 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer screening, risk reduction, and treatment
Number of subjects: 117
Study 35367908 — intervention group
Group type: EXPERIMENTAL
Intervention: Family connections and shared experiences
Number of subjects: 117
Study 35367908 — intervention group
Group type: EXPERIMENTAL
Intervention: Objectification of the body
Number of subjects: 117
Study 35367908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pain or loss experiences
Number of subjects: 117
Study 35368221 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream applied twice daily for 28 days, then continued on active lesions for an additional 28 days (extension period).
Number of subjects: 41
Study 35368221 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% ruxolitinib cream
Number of subjects: 41
Study 35368281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular movement (MM) monitoring with machine learning analysis
Number of subjects: 31
Study 35368281 — intervention group
Group type: COMPARATOR
Intervention: In-home polysomnography (PSG)
Number of subjects: 31
Study 35368514 — intervention group
Group type: EXPERIMENTAL
Intervention: Training load and genotype
Number of subjects: 300
Study 35368551 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise combined with dietary restriction (3 times per week for 12 weeks)
Number of subjects: 60
Study 35368551 — intervention group
Group type: COMPARATOR
Intervention: Dietary restriction only (control group)
Number of subjects: 60
Study 35368811 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based supportive care change package consisting of 14 best-practice recommendations for kidney failure care, including systematic identification of seriously ill patients, goals-of-care conversations, and care options to respond to patient wishes.
Number of subjects: 0
Study 35369018 — intervention group
Group type: EXPERIMENTAL
Intervention: p-inulin (8 g twice daily for 12 weeks)
Number of subjects: 13
Study 35369018 — intervention group
Group type: COMPARATOR
Intervention: No treatment (pretreatment phase)
Number of subjects: 13
Study 35369018 — intervention group
Group type: EXPERIMENTAL
Intervention: p-inulin
Number of subjects: 13
Study 35369096 — intervention group
Group type: EXPERIMENTAL
Intervention: e-Diary mobile food record
Number of subjects: 365
Study 35369374 — intervention group
Group type: EXPERIMENTAL
Intervention: Medications containing acid salts (Metformin hydrochloride at 2550 mg/d and Gabapentin hydrochloride at 2700 mg/d)
Number of subjects: 74
Study 35369374 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride (15.4 meq/d)
Number of subjects: 74
Study 35369374 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin hydrochloride (13.0 meq/d)
Number of subjects: 74
Study 35369607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (10 mg/kg) plus Gefitinib (250 mg/d)
Number of subjects: 82
Study 35369646 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial tortuosity index in AIS patients
Number of subjects: 249
Study 35369646 — intervention group
Group type: COMPARATOR
Intervention: Control group (83 subjects)
Number of subjects: 249
Study 35369646 — intervention group
Group type: EXPERIMENTAL
Intervention: Tortuosity of left carotid artery system and vertebral artery
Number of subjects: 249
Study 35369714 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving hospital with shared hospital affiliation
Number of subjects: 73114
Study 35369714 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving hospital with teaching hospital status
Number of subjects: 73114
Study 35369714 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving hospital with stroke center status
Number of subjects: 73114
Study 35369714 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving hospital with same or higher reputational ranking
Number of subjects: 73114
Study 35369854 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccines
Number of subjects: 139
Study 35369854 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 139
Study 35370021 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-targeted biopsy
Number of subjects: 181
Study 35370021 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 181
Study 35370021 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal ablation
Number of subjects: 181
Study 35370573 — intervention group
Group type: COMPARATOR
Intervention: Constant practice (CG) - practicing one pattern of step isometric contractions during unimanual index finger abduction, 90 trials in all training sessions.
Number of subjects: 50
Study 35370573 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable practice (VG) - practicing three different patterns, each practiced 30 times per session.
Number of subjects: 50
Study 35370573 — intervention group
Group type: COMPARATOR
Intervention: Constant practice (CG) - EEG activation and connectivity between cognitive, sensory, and motor cerebral cortex areas.
Number of subjects: 50
Study 35370573 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable practice (VG) - EEG activation and connectivity between cognitive, sensory, and motor cerebral cortex areas.
Number of subjects: 50
Study 35370573 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CG and VG) - motor task proficiency examined before (pre-) and after practice (post- and retention tests).
Number of subjects: 50
Study 35371427 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetrombopag (7.5 mg once daily to a maximum of 15 mg once daily for 52 weeks)
Number of subjects: 55
Study 35371427 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetrombopag
Number of subjects: 55
Study 35371993 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine
Number of subjects: 566
Study 35371993 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine
Number of subjects: 566
Study 35372008 — intervention group
Group type: EXPERIMENTAL
Intervention: ADP-A2M10
Number of subjects: 10
Study 35372393 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide (HC) plus chronic transfusion regimen
Number of subjects: 1579
Study 35372393 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute transfusion approaches
Number of subjects: 1579
Study 35372393 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloimmunization
Number of subjects: 1579
Study 35372393 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-recipient exact matching for ABO, Rhesus, and Kell antigen systems
Number of subjects: 1579
Study 35372473 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution impedance manometry (HRIM)
Number of subjects: 14
Study 35372734 — intervention group
Group type: EXPERIMENTAL
Intervention: MoAb
Number of subjects: 235
Study 35372734 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 235
Study 35373037 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular access support quality improvement program
Number of subjects: 37
Study 35373037 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-program self-efficacy
Number of subjects: 37
Study 35373037 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-program self-efficacy
Number of subjects: 37
Study 35373037 — intervention group
Group type: EXPERIMENTAL
Intervention: Program acceptability
Number of subjects: 37
Study 35373040 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB)
Number of subjects: 350
Study 35373040 — intervention group
Group type: EXPERIMENTAL
Intervention: Lawton Instrumental Activities of Daily Living (IADL)
Number of subjects: 350
Study 35373040 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mini-Mental Status Exam (M3SE)
Number of subjects: 350
Study 35373105 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 mRNA vaccines (BNT162b2 [BioNTech/Pfizer] or mRNA-1273 [Moderna])
Number of subjects: 60
Study 35373105 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 35373179 — intervention group
Group type: EXPERIMENTAL
Intervention: Momentary self-regulation measure (four subscales: momentary perseverance, momentary sensation seeking, momentary self-judgment, momentary mindfulness)
Number of subjects: 185
Study 35373179 — intervention group
Group type: EXPERIMENTAL
Intervention: Momentary self-regulation in smoking sample
Number of subjects: 185
Study 35373179 — intervention group
Group type: EXPERIMENTAL
Intervention: Momentary self-regulation in binge-eating sample
Number of subjects: 185
Study 35373179 — intervention group
Group type: EXPERIMENTAL
Intervention: Laddr mobile application
Number of subjects: 185
Study 35373299 — intervention group
Group type: EXPERIMENTAL
Intervention: ADXS31-142 monotherapy (n = 13)
Number of subjects: 50
Study 35373299 — intervention group
Group type: EXPERIMENTAL
Intervention: ADXS31-142 plus pembrolizumab (n = 37)
Number of subjects: 50
Study 35373299 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study 35373878 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 RA
Number of subjects: 11430
Study 35373878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11430
Study 35377104 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of aerobic exercise intervention
Number of subjects: 144
Study 35377104 — intervention group
Group type: COMPARATOR
Intervention: Attention-control
Number of subjects: 144
Study 35377133 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam 12/1.5 g/24 h as a continuous infusion
Number of subjects: 39